Table 2 A characteristics of patients included in the analysis 6 months after initiation of nintedanib treatment in study 2
Parameters | 6Â M responders (n=14) | 6Â M non-responders (n=6) | P value |
|---|---|---|---|
Age, years | 74.5 (67-78) | 71.5 (68.3-75) | n.s |
Gender, Male/Female | 10/4 | 4/2 | n.s |
BMI | 23.6 (18.9-26.4) | 23.5 (20.3-27.4) | n.s |
BSA (m2) | 1.61 (1.53-1.70) | 1.74 (1.54-1.90) | n.s |
FEV1/FVC (G)(%) | 87.1 (80.8-91.3) | 87.1 (80.4-87.1) | n.s |
FVC (ml) | 2170 (1758-2463) | 1980 (1195-2503) | n.s |
%FVC (%) | 68.9 (52.9-76.0) | 61.3 37.1-81.1) | n.s |
KL-6 (U/mL) | 943.5 (538.8-1800) | 1140 (754.0-1788) | n.s |